Trial Profile
A Randomized, Open-label, Cross-over Adaptive Study of the Comparative Pharmacokinetics and Bioequivalence of the Drugs Molnupiravir, Capsules, 200 mg and Lagevrio, Capsules, 200 mg in Healthy Volunteers at Fasted Conditions
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Molnupiravir (Primary)
- Indications Chikungunya virus infections; COVID 2019 infections; Eastern equine encephalomyelitis; Ebola virus infections; Influenza virus infections; Middle East respiratory syndrome coronavirus; Renal failure; Respiratory syncytial virus infections; Severe acute respiratory syndrome; Venezuelan equine encephalomyelitis
- Focus Pharmacokinetics
- Sponsors Valenta
- 31 Jul 2023 New trial record